Broadview Ventures

Broadview Ventures is a mission-driven, non-profit-affiliated venture investor focused on cardiovascular and neurological diseases, deploying capital from the Leducq Foundation. The mandate is unusually narrow and unusually mission-aligned: they fund early-stage companies developing therapeutics, diagnostics, and medical devices targeting cardiovascular and neurovascular disease, including stroke, heart failure, and atherosclerosis. For healthcare AI founders, Broadview is the right partner if your platform directly addresses these therapeutic areas — AI-driven cardiovascular diagnostics, stroke-detection imaging, neuro-monitoring, predictive risk-stratification for cardiac populations — and you are at the seed or Series A stage with strong scientific validation. Check sizes are plausibly $500K to $3M, with willingness to lead in their domain and to syndicate alongside biotech and medtech specialists. Founders who should approach: technically credentialed teams with peer-reviewed scientific data, clinical advisors in cardiovascular or neurological medicine, and a clear regulatory pathway to clinical use. Founders who should not approach: anything outside the cardiovascular and neurological remit — oncology, immunology, primary care software, mental health, dermatology — these are not in scope and pitching them wastes both sides’ time. Entry path is warm introduction through the Leducq Foundation network, academic cardiovascular and neurology research institutions, or co-investors active in the space. Their LinkedIn and Crunchbase profiles list portfolio companies that map the typical deal. Be prepared for diligence that emphasizes clinical evidence, regulatory pathway, and impact alignment with the foundation’s scientific mission. This is a high-conviction, narrow-mandate partner — use them if you fit, deprioritize if you do not.